134069-68-4
|
|
- CAS号:
- 134069-68-4
- 英文名:
- TDN 345
- 英文别名:
- TDN 345;TDN345,TDN-345;1-Oxa-3,8-diazaspiro[4.5]decan-2-one, 8-[4,4-bis(4-fluorophenyl)butyl]-3-(1,1-dimethylethyl)-4-methylene-
- 中文名:
- 134069-68-4
- 中文别名:
- 化合物 T13107
- CBNumber:
- CB71349107
- 分子式:
- C28H34F2N2O2
- 分子量:
- 468.58
- MOL File:
- 134069-68-4.mol
|
|
|
134069-68-4化学性质
-
沸点:
-
556.2±60.0 °C(Predicted)
-
|
-
密度:
-
1.18±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
Soluble in DMSO
-
|
-
酸度系数(pKa):
-
9.67±0.20(Predicted)
-
|
134069-68-4性质、用途与生产工艺
TDN345 A 是一种 Ca2+ 拮抗剂,主要用于血管和老年痴呆疾病,例如阿尔茨海默症的研究。
TDN-345 (10 μM) significantly increases the intracellular NGF content in the time-course study. TDN-345 induces NGF synthesis/secretion at the concentrations of 0.1 μM; statistically significant at 1 μM. The ED
50
is 0.88 μM.
TDN-345 (0.1-1.0 mg/kg, p.o.) dose-dependently decreases the mortality and ischemic neurological deficit score when administered orally twice, 60 min before ischemia and 90 min after recirculation. Additionally, TDN-345 (0.2 or 1.0 mg/kg, p.o. once daily for 3 weeks after the onset of stroke) decreases the mortality and recurrence of stroke in SHRSP.
134069-68-4
上下游产品信息
上游原料
下游产品
134069-68-4, 134069-68-4 相关搜索:
- C28H34F2N2O2
- 化合物 T13107
- 134069-68-4
- TDN345,TDN-345
- 1-Oxa-3,8-diazaspiro[4.5]decan-2-one, 8-[4,4-bis(4-fluorophenyl)butyl]-3-(1,1-dimethylethyl)-4-methylene-
- TDN 345